1999
DOI: 10.1016/s0040-4039(98)02364-8
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of 9-fluorenylmethyl esters using 9-fluorenylmethylchloroformate

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0

Year Published

2000
2000
2014
2014

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(11 citation statements)
references
References 7 publications
0
11
0
Order By: Relevance
“…The latter method is also used for the preparation of Fm esters 118, 119. Alternatively, these esters can be obtained from 9‐fluorenylmethylchloroformate in the presence of DIEA/DMAP120 or by transesterification of p ‐nitrophenyl esters in the presence of imidazole 121…”
Section: C‐terminal Carboxyl Protecting Groupsmentioning
confidence: 99%
“…The latter method is also used for the preparation of Fm esters 118, 119. Alternatively, these esters can be obtained from 9‐fluorenylmethylchloroformate in the presence of DIEA/DMAP120 or by transesterification of p ‐nitrophenyl esters in the presence of imidazole 121…”
Section: C‐terminal Carboxyl Protecting Groupsmentioning
confidence: 99%
“…The latter was synthesized starting from the known Boc-Phe-OFM [27] which, after removal of the Boc group from its N-terminus, was first acylated with Chpca(MOM)-OH (10) and then O-MOM-deprotected to furnish the acylamino acid 23 in 82 % yield over three steps. Finally, the HATU-mediated acylation of H-(NO 2 )Nle-Phe-Val-OMe with Chba-OH (3-chloro-2-hydroxybenzoic acid) yielded 21e in 45 % yield.…”
Section: Substance Fedmentioning
confidence: 99%
“…[3b] HOAt, [31] Chpca(MOM)-OH (10), [9] racemic (2-nitrophenyl)alanine (18), [16] Boc-Phe-Val-OMe (19), [21] Boc-Phe-OFM (22), [27] Chpca(MOM)-(3-Ncp)Ala-OFM (24), [9] PyAOP [31] were prepared as described previously elsewhere. Feeding experiments and biological assays were carried out as described elsewhere.…”
Section: Generalmentioning
confidence: 99%
“…Hydrolysis of the nitrile group in the intermediate 105 according to protocol Cacchi et al [103] led to the amide 106 (all attempts to hydrolyze 105 or 106 were unsuccessful) which, in turn, was doubly acylated with Boc 2 O to give the desired triacylated intermediate 107 together with the side product 108. The alkaline hydrolysis of 107 [104] Phenylalanine 9-fluorenylmethyl ester 111 obtained after Boc-group removal from N-termini of N-Boc protected amino ester 110 [105] with 5 M HCl in Et 2 O was coupled with the acid 109 using the combination of N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) to give the acyl amino ester 112 in 93% yield, which after removal of the methoxymethyl group with MgBr 2 ⋅Et 2 O and ethyl mercaptan in diethyl ether [106] gave the ester 113 (88%). The latter was deprotected using 20% diethylamine in CH 2 Cl 2 to give the unstable 114 in 100% crude yield, which was immediately coupled with the dipeptide 118 obtained after deprotection of the peptide 117 with 5 M HCl in Et 2 O, which was previously prepared from N-Boc protected phenylalanine 115 and valine methyl ester 116 using dicyclohexylcarbodiimide (DCC) and HOBt in 82% yield, using the O-(7-azabenzotriazole-1yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) [107] to give the desired acyltripeptide 119 in 23% yield.…”
Section: Scheme 28mentioning
confidence: 99%
“…(2S,4R)-4-Tosyloxi-N-Boc-proline, [22] tert-butyl (R)-N-(tert-butyloxycarbonyl)pyroglutamate [as it was described for (S)-isomer], [34] tert-butyl (2R,4R)-(N-tert-butyloxycarbonyl)-4-allylpyroglutamate [as it was described for (2S,4S)-isomer], [35] methyl (2S,4R)-(N-tertbutyloxycarbonyl)-4-hydroxyprolinate, [46] methyl (2S,4RS)-(N-tert-butyloxycarbonyl)-4iodopro-linate, [47] (2S,4R)-(N-tert-butyloxycarbonyl)-4-hydroxyproline, [53] , (2S,4R)-(N-tertbutyloxy-carbonyl)-4-mesyloxyprolinol, [57] (2S,4R)-(N-tert-butyloxycarbonyl)-4-hydroxyprolixnol tert-butyldimetylsilyl ester, [62] adduct of (2S,4R)-4-hydroxyproline and pivalic aldehyde, [64] rac-(trans-2'-nitrocyclopropyl)methanol, [84] (1,1-dideutero)ethyltriphenylphosphonium bromide, [72] (R)-allo-threonine, [75] (4R)-phenyloxazolidinone-2, [80] (4R)-4-phenyl-3-(3'phenylbutyryl)oxazo-lidinone-2, [79] (4R,3'S)-4-phenyl-3-(3'-phenylbutyryl)oxazolidinone-2 [as it was described for (4S,3'R)-isomer], [81] 1,1,3,3-tetramethyl guanidinium azide, [136] rac-βmethylphenylalanine, [137] (2S,3R)-β-methylphenylalanine, [79] (S) and (R) Belokon's chiral glycine equivalents, [86] (4R)-4-isopropyl-1,3-trans-(2'-nitrocyclopropyl)carbonyloxazolidinones-2, [14] trans-(2'-nitrocyclopro-pyl)methyl iodide, [80] 1-methoxysuccinimide, [97] 2-amino-6chloropyridine, [99] 2-acetamido-6-chloropyridine, [101] 2,6-dichloropyridine-N-oxide, [102] 9flourenylmethyl (S)-(N-tert-butyloxycarbonyl)phenylalaninate, [105] 2-acetamino-6-aminopyridine, [107] (S)-(2-nitrophenyl)sulfenylproline, [116] (S)-(2-nitrophenyl)sulfenylisoleucine, [116] methyl (N-tert-butyloxycarbonyl)-isoleucyl-prolinate, [117] p-nitrobenzyl (R)-allo-(N-tert-butyloxycarbonyl)threoninate [as it was described for (S)-threo-isomer], [120] (2S,3R)-(N-9-fluorenylmethyloxycarbonyl)-β-methylphenylalanine, …”
Section: Compoundmentioning
confidence: 99%